STING1 and neoplasm: Given that the efficacy of AVA-NP-695 stabilizes 2′3′-cGAMP levels to activate the STING pathway, leading to cytokine release, we evaluated its potency in vivo to inhibit tumor growth in the 4T1 TNBC syngeneic model, which is known to be immune-checkpoint non-responsive [46].